Ipsen (FR:IPN) has released an update.
Ipsen has expanded its oncology research partnership with Marengo Therapeutics to include new preclinical development collaborations for ‘T-Cell Engager’ assets via Marengo’s TriSTAR platform. These efforts aim to activate T lymphocytes against ‘cold’ tumors, which are challenging to treat with traditional therapies. The agreement includes an initial payment to Marengo with potential milestone payments totaling up to $1.2 billion, plus tiered royalties on global sales.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.
